NCT00969917View on ClinicalTrials.gov

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Dedifferentiated Liposarcoma
Interventions
DRUG

IPI-504

IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Infinity Pharmaceuticals, Inc.

INDUSTRY